Clinical trials: Inflammatory
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Graft vs Host Disease
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).
- Trial name
- NCT02841995
- Testing
- Belumosudil (KD025)
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Kadmon, a Sanofi Company
Systemic Lupus Erythematosus, Arthritic Psoriasis
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165…
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03254784
- Testing
- BMS-986165 Capsule, BMS-986165 Tablet
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Blood Stream Infection, Blood Stream Infections
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
This study is designed to evaluate the clinical performance of the UllCORE Bloodstream Infection (BSI) Test, an investigational molecular diagnostic test intended to detect microorganisms and selected antimicrobial resistance…
- Conditions
- Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
- Trial name
- B-RAPID (NCT07859852)
- Testing
- UllCORE BSI Test
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 1,500 people
- Sponsor
- Deepull Diagnostics S.L.
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
Ulcerative Colitis
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
This is a multi-center, randomized, parallel arm, double-blind study with approximately 750 participants with moderately to severely active Colitis Ulcerosa randomized to receive either PB016 or Entyvio®
- Trial name
- UCESIVE (NCT05771155)
- Testing
- Intravenous (IV) infusions
- Where
- Georgia
- Volunteers
- 750 people
- Sponsor
- Polpharma Biologics S.A.
Crohn's Disease
Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
The objectives of this study were to assess the safety and tolerability of LDP-02 in patients with active Crohn's disease who were not receiving corticosteroids or immunosuppressives, to assess the ability of LDP-02 to reduce…
- Trial name
- NCT00655135
- Testing
- LDP-02
- Volunteers
- 185 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Ulcerative Colitis
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis
This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis.
- Trial name
- NCT00073021
- Testing
- Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
- Where
- 57 sites in United States, Canada and 1 more
- Volunteers
- 386 people
- Sponsor
- Warner Chilcott
Bloodstream Infection
Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection
Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in septic patients with suspected, life-threatening bloodstream infection
- Trial name
- NCT04260789
- Testing
- Seraph 100,The Microbind Affinity Blood Filter
- Where
- 25 sites in Austria, Belgium and 7 more
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- ExThera Medical Europe BV
Cataract
Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification.
- Trial name
- PRO-145/III (NCT03693989)
- Testing
- Difluprednate 0.05%, Prednefrin
- Where
- 5 sites in Mexico
- Volunteers
- 178 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Ulcerative Colitis
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14…
- Trial name
- NCT00457171
- Testing
- GI-270384
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Respiratory Tract Infections, Urinary Tract Infections
Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)
This study aims to evaluate the diagnostic and prognostic performance of a novel mRNA diagnostic/prognostic classifier (interprets the expression of 29 host response mRNA biomarkers) from whole blood in adult patients presenting…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- NCT05639504
- Testing
- IMX-BVN-4 and IMX-SEV-4
- Sponsor
- Inflammatix
Metabolic Syndrome, Hypertension
Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome
The purpose of this study is to study the effect of two doses of olmesartan medoxomil and amlodipine on vascular markers in hypertensive patients with metabolic syndrome.
- Trial name
- VAMOS (NCT00891267)
- Testing
- Olmesartan medoxomil tablets low dose, Olmesartan medoxomil tablets high dose, Amlodipine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Asthma
Roflumilast Plus Montelukast in Adults With Severe Asthma
This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
- Trial name
- NCT01765192
- Testing
- Roflumilast, Montelukast
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Invasive Candidiasis, Candidemia
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
- Trial name
- NCT00189709
- Testing
- Micafungin, fluconazole
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Anemia, Iron Deficiency, Inflammatory Bowel Diseases
Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH )
The aim of the study is to understand the early experiences of Feraccru® in patients with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including treatment effectiveness, patterns of use and…
- Trial name
- FRESH (NCT03247816)
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Shield Therapeutics
LRTI, Sepsis
Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis
The TAILORED-Treatment consortium was established to develop new tools aimed to increase the effectiveness of antibiotic and antifungal therapy, reduce adverse events, and help limit the emergence of antimicrobial resistance in…
- Conditions
- LRTI, Sepsis, Fungal Infections, Bacteremia
- Trial name
- TailoredT (NCT02025699)
- Where
- Israel
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Acne Vulgaris, Acne Vulgaris Superficial Mixed Comedonal and Inflammatory
Full Spectrum Hemp Observational Study
In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women…
- Trial name
- NCT04730414
- Testing
- Full-spectrum hemp (0.018% THC)
- Volunteers
- 50 people
- Sponsor
- Charlotte's Web, Inc
Ulcerative Colitis
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
This study will evaluate the efficacy, safety and tolerability of AEB071 in the treatment of active, moderate to severe ulcerative colitis in patients who have failed conventional therapy using mesalamine or steroids
- Trial name
- NCT00572585
- Testing
- AEB071
- Where
- 20 sites in United States, Denmark and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Mucosal Healing Study in Crohn's Disease (CD)
The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.
- Trial name
- MUSIC (NCT00297648)
- Testing
- Certolizumab pegol
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 89 people
- Sponsor
- UCB Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.